Cargando…
Summary of worldwide pediatric malignancies reported after exposure to etanercept
BACKGROUND: Concerns have been raised about a potential link between the use of TNF inhibitors and development of malignancy in the pediatric population. We examined the worldwide experience of etanercept use in pediatric patients and the occurrence of malignancies as reported from clinical trials,...
Autores principales: | McCroskery, Peter, Wallace, Carol A, Lovell, Daniel J, Stryker, Scott, Chernyukhin, Nataliya, Blosch, Consuelo, Zack, Debra J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904755/ https://www.ncbi.nlm.nih.gov/pubmed/20546618 http://dx.doi.org/10.1186/1546-0096-8-18 |
Ejemplares similares
-
Myostatin negatively regulates satellite cell activation and self-renewal
por: McCroskery, Seumas, et al.
Publicado: (2003) -
Etanercept-Induced Myelopathy in a Pediatric Case of Blau Syndrome
por: Caracseghi, Fabiola, et al.
Publicado: (2011) -
Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports
por: Hooper, Michele, et al.
Publicado: (2013) -
A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis
por: Cardiel, Mario H, et al.
Publicado: (2010) -
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
por: Strand, Vibeke, et al.
Publicado: (2012)